摘要
目的：系统评价洛铂对比顺铂在中国肺癌患者治疗中效果。方法：计算机检索Cochrane Library、Pub Med、Medline、EM-base、Wan Fang Data、CNKI、维普等数据库,收集洛铂对比顺铂在中国肺癌患者治疗中效果的随机对照试验（RCT）,检索时限均从建库至2014年2月。两名研究者按照纳入排除标准独立筛选文献、提取资料和质量评价后,采用Rev Man 5.1软件进行Meta分析。结果：纳入12个RCT,Meta分析结果显示,本文分析结果提示两组3~4级副反应发生率差异存在统计学显著性,洛铂组恶心呕吐的治疗副反应明显低于顺铂治疗组。但是两组疾病控制率、部分缓解率和完全缓解率没有统计学差异;血小板减低等副反应发生率也没有统计学差异。由于纳入研究的质量和数量有限,故本系统评价的结论仅供临床实践与研究参考。结论：本研究结果提示新一代铂类药物洛铂在中国肺癌患者治疗中与传统铂类药物效果近似,但是副反应较小,具有一定优越性,有临床推广价值。
AIM： To evaluate lobaplatin contrast cisplatin for treatment of lung cancer in Chinese patients. METHODS： We searched the Cochrane Library, Pub Med, Medline, EM-base, Wan Fang Data,CNKI,VIP and other databases to collect random lobaplatin contrast the treatment of lung cancer patients in China,the effect of randomized control trial（ RCT）,were retrieved from the construction time library to Feburary 2014. Two researchers independently screened according to inclusion and exclusion criteria literature,data extraction and quality assessment after using Rev Man 5. 1 software Meta-analysis. RESULTS： Among the 12 RCT,Meta analysis showed that the two-stage analysis indicated the incidence of side effects was statistically significant difference,side effects including nausea and vomiting in lobaplatin group was significantly lower than that of cisplatin treatment groups. But the two disease control rate,partial response rate and complete remission rate showed no statistical significance.Platelets to reduce the incidence of side effects such as differences are not statistically significant. Due to limited quantity and quality of included studies,the conclusions of this systematic review only offer clinical reference. CONCLUSION： The results of this study suggest that a new generation platinum drug lobaplatin,for the treatment of lung cancer patients in China was similar to the traditional platinum drugs,but with less side effects and thus has some advantages.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2015年第6期653-659,共7页
Chinese Journal of Clinical Pharmacology and Therapeutics
关键词
肺癌
洛铂
顺铂
化疗
随机对照试验
META分析
lung cancer
lobaplatin
cisplatin
chemotherapy
randomized control trials
Meta analysis
